El libro de la cámara del conde, mi señor: una fuente para el estudio del lujo en la corte de los condes de Plasencia a mediados del siglo XV (1453-1455)

Autor: Francisco de Paula Cañas Gálvez

Publikováno v: Historia. Instituciones. Documentos, Vol 41, Pp 99-145 (2014)

El libro de la cámara del conde, mi señor, is a source of extraordinary value for the courtiers areas of late medieval castilian high nobility. Quoted partially along the last decades by different scholars of the nobility of the period, is now publ

Externí odkaz: https://doaj.org/article/8e7de9bba0c2462fa834de80a3cc7736

Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.

Autor: Gómez E; Hospital Universitario 12 De Octubre, Madrid, Spain., Montero JL; Hospital Universitario Reina Sofia, Córdoba, Spain., Molina E; Complexo Hospitalario Universitario De Santiago, Coruña, Spain., García-Buey L; Hospital Universitario De La Princesa, Madrid, Spain., Casado M; Hospital Universitario de Torrecárdenas, Almería, Spain., Fuentes J; Hospital Universitario Miguel Servet, Zaragoza, Spain., Simón MA; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.; University of Zaragoza, Zaragoza, Spain., Díaz-González A; Hospital Universitario Marqués de Valdecilla, Santander, Spain., Jorquera F; Complejo Hospitalario de Leon, Leon, Spain., Morillas RM; Hospital Germans Trias i Pujol, Badalona, Spain., Presa J; Centro Hospitalar Tras-os-Montes a Alto Douro, Vila Real, Portugal., Berenguer M; Hospital Universitario La Fe, Valencia, Spain.; University of Valencia, Valencia, Spain., Conde MI; Hospital Universitario La Fe, Valencia, Spain., Olveira A; Hospital Universitario La Paz, Madrid, Spain., Macedo G; Serviço de Gastrenterologia Do Centro Hospitalar Universitário São João (CHUSJ), Porto, Portugal., Garrido I; Serviço de Gastrenterologia Do Centro Hospitalar Universitário São João (CHUSJ), Porto, Portugal., Hernández-Guerra M; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain., Olivas I; Hospital Clinic, Barcelona, Spain., Rodríguez-Tajes S; Hospital Clinic, Barcelona, Spain., Londoño M; Hospital Clinic, Barcelona, Spain., Sousa JM; Hospital Universitario Virgen del Rocio, Sevilla, Spain., Ampuero J; Hospital Universitario Virgen del Rocio, Sevilla, Spain.; Instituto De Biomedicina De Sevilla (IBIS), Sevilla, Spain., Romero-González E; Hospital Clinico Universitario de Valencia, Universidad de Valencia, Valencia, Spain., González-Padilla S; Hospital Clinico Universitario de Valencia, Universidad de Valencia, Valencia, Spain., Escudero-García D; Hospital Clinico Universitario de Valencia, Universidad de Valencia, Valencia, Spain., Carvalho A; Centro Hospitalar e Universitário De Coimbra, Coimbra, Portugal., Santos A; Centro Hospitalar e Universitário De Coimbra, Coimbra, Portugal., Gutiérrez ML; Hospital Universitario Fundacion Alcorcon, Alcorcon Madrid, Spain.; University Rey Juan Carlos, Madrid, Spain., Pérez-Fernández E; Hospital Universitario Fundacion Alcorcon, Alcorcon Madrid, Spain.; University Rey Juan Carlos, Madrid, Spain., Aburruza L; Hospital Universitario de Donostia, Donostia-San Sebastián, Spain., Uriz J; Complejo Hospitalario de Navarra, Pamplona, Spain., Gomes D; Departamento de Gastrenterología, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal., Santos L; Departamento de Gastrenterología, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal., Martínez-González J; Hospital Universitario Ramón y Cajal, Madrid, Spain., Albillos A; Hospital Universitario Ramón y Cajal, Madrid, Spain.; Ramón y Cajal Institute of Health Research, Madrid, Spain.; University of Alcalá de Henares, Alcalá de Henares, Spain., Fernández-Rodríguez CM; Hospital Universitario Fundacion Alcorcon, Alcorcon Madrid, Spain.; University Rey Juan Carlos, Madrid, Spain.

Publikováno v: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2024 Jun; Vol. 59 (12), pp. 1604-1615. Date of Electronic Publication: 2024 May 01.

Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study.

Autor: Matarraz S; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. smats@usal.es.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain. smats@usal.es., Leoz P; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Yeguas-Bermejo A; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., van der Velden V; Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Bras AE; Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Sánchez Gallego JI; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Lecrevisse Q; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Ayala-Bueno R; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Teodosio C; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Criado I; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., González-González M; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain., Flores-Montero J; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Avendaño A; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Vidriales MB; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Chillón MC; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., González T; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., García-Sanz R; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Prieto Conde MI; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Hematology Department, University Hospital of Salamanca, CIBERONC (CB16/12/00233), IBSAL, Accelerator program and Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca), Salamanca, Spain., Villamor N; Hematology Service, Hospital Clinic, Barcelona, Spain., Magnano L; Hematology Service, Hospital Clinic, Barcelona, Spain., Colado E; Hematology Department and Laboratory Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Fernández P; FACS/Stem Cell Laboratory, Kantonsspital Aarau, Aarau, Switzerland., Sonneveld E; Dutch Childhood Oncology Group, The Hague, The Netherlands., Philippé J; Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium., Reiterová M; CLIP-Department of Pediatric Hematology and Oncology, Second Medical Faculty, Charles University and University Hospital Motol, Prague, Czech Republic., Caballero Berrocal JC; Department of Hematology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Diaz-Gálvez FJ; Department of Hematology, Hospital Universitario de Burgos, Burgos, Spain., Ramos F; Department of Hematology, Complejo Asistencial Universitario de León, León, Spain., Dávila Valls J; Department of Hematology, Complejo Asistencial de Ávila, Ávila, Spain., Manjón Sánchez R; Department of Hematology, Complejo Asistencial de Zamora, Zamora, Spain., Solano Tovar J; Department of Hematology, Complejo Asistencial Universitario de Palencia, Palencia, Spain., Calvo X; Pathology Service, Hospital del Mar, Barcelona, Spain., García Alonso L; Hematology Service, University Hospital of Getafe, Madrid, Spain., Arenillas L; Pathology Service, Hospital del Mar, Barcelona, Spain., Alonso S; Hematology Department and Laboratory Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Fonseca A; Hematology Department and Laboratory Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Quirós Caso C; Hematology Department and Laboratory Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain., van Dongen JJM; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., Orfao A; Translational and Clinical Research Program, Centro de Investigación del Cáncer (IBMCC; CSIC-University of Salamanca); Cytometry Service, NUCLEUS; Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. orfao@usal.es.; Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain. orfao@usal.es.

Publikováno v: Blood cancer journal [Blood Cancer J] 2023 Sep 04; Vol. 13 (1), pp. 132. Date of Electronic Publication: 2023 Sep 04.

Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study

Autor: Ocio EM, Herrera P, Olave MT, Castro N, Pérez-Simón JA, Brunet S, Oriol A, Mateo M, Sanz MÁ, López J, Montesinos P, Chillón MC, Prieto-Conde MI, Díez-Campelo M, González M, Vidriales MB, Mateos MV, San Miguel JF, PETHEMA Group

Publikováno v: HAEMATOLOGICA
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

This phase Ib/II trial combined the pan-deacetylase inhibitor panobinostat with chemotherapy followed by panobinostat maintenance in elderly patients with newly diagnosed acute myeloid leukemia. Patients with prior history of myelodysplastic syndrome

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::e216d7923ee7c5196e10d8e824408ed1
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1313

Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design.

Autor: Aguilera-Diaz A; Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Vazquez I; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain., Ariceta B; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain., Mañú A; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain., Blasco-Iturri Z; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain., Palomino-Echeverría S; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain., Larrayoz MJ; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain., García-Sanz R; Hematology Department, University Hospital of Salamanca, IBSAL and CIBERONC, Salamanca, Spain., Prieto-Conde MI; Hematology Department, University Hospital of Salamanca, IBSAL and CIBERONC, Salamanca, Spain., Del Carmen Chillón M; Hematology Department, University Hospital of Salamanca, IBSAL and CIBERONC, Salamanca, Spain., Alfonso-Pierola A; Hematology Department, Clinica Universidad de Navarra (CUN), Pamplona, Spain., Prosper F; Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Hematology Department, Clinica Universidad de Navarra (CUN), Pamplona, Spain., Fernandez-Mercado M; Advanced Genomics Laboratory, Hemato-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.; Biomedical Engineering Department, School of Engineering, University of Navarra, San Sebastian, Spain., Calasanz MJ; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Hematological Diseases Laboratory, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.; Scientific Co-Director of CIMA LAB Diagnostics, CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain.

Publikováno v: PloS one [PLoS One] 2020 Jan 24; Vol. 15 (1), pp. e0227986. Date of Electronic Publication: 2020 Jan 24 (Print Publication: 2020).